---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-056782"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:33:43.994217+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iovance Q1 revenue $71M (+45% YoY); guides FY26 $350-370M; endometrial cancer 40% cORR

## Summary
- Total product revenue ~$71M in Q1 2026, up 45% YoY; U.S. Amtagvi revenue ~$60M, Proleukin ~$11M.
- FY 2026 revenue guidance $350-$370M; Q2 2026 guidance $86-$88M.
- Lifileucel in metastatic serous endometrial cancer: 40% confirmed ORR, 100% DCR in first 5 patients; FDA expedited path planned.
- Cash ~$319M, expected to fund operations into 2028; R&D expenses down 12% vs Q4 2025.
- UK MAA for lifileucel withdrawn for procedural reasons, will resubmit; EMA resubmission planned for 2026.

## SEC filing metadata
- accession: 0001104659-26-056782
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/0001104659-26-056782-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/tm2613648d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-056782
- JSON: https://secwatch.observer/filing/0001104659-26-056782.json
- Plain text: https://secwatch.observer/filing/0001104659-26-056782.txt

## Key facts
- Earnings Releases
  IOVANCE BIOTHERAPEUTICS, INC. reported Full year 2026 results: revenue $350 million to $370 million. Guidance initiated.
  - Period: Full year 2026
  - Revenue: $350 million to $370 million
  - Guidance: initiated
  - Result: guidance update
  source text: Total product revenue guidance for 2Q26 is $86 million to $88 million and for FY26 is $350 million to $370 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/0001104659-26-056782-index.htm
- Earnings Releases
  IOVANCE BIOTHERAPEUTICS, INC. reported Second quarter 2026 results: revenue $86 million to $88 million. Guidance initiated.
  - Period: Second quarter 2026
  - Revenue: $86 million to $88 million
  - Guidance: initiated
  - Result: guidance update
  source text: Total product revenue guidance for 2Q26 is $86 million to $88 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/0001104659-26-056782-index.htm
- Earnings Releases
  IOVANCE BIOTHERAPEUTICS, INC. reported first quarter ended March 31, 2026 results: revenue ~$71 million.
  - Period: first quarter ended March 31, 2026
  - Revenue: ~$71 million
  - Result: reported results
  source text: and long-term value for patients and shareholders.” First Quarter 2026 Financial Highlights Continued Strength in Execution and Cost Discipline · Total product revenue of ~$71 million increased by ~45% over 1Q25, reflecting significant performance improvements over the prior annual maintenance period. o U.S. Amtagvi revenue was ~$60 million. o Global
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/0001104659-26-056782-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.